Biomarkers in Alzheimer's disease drug development

被引:106
作者
Blennow, Kaj [1 ]
机构
[1] Univ Gothenburg, Clin Neurochem Lab, Inst Neurosci & Physiol, Dept Psychiat & Neurochem,Sahlgrenska Acad, Molndal, Sweden
关键词
MILD COGNITIVE IMPAIRMENT; BETA IMMUNIZATION AN1792; PLACEBO-CONTROLLED TRIAL; A-BETA; CEREBROSPINAL-FLUID; CSF BIOMARKERS; GAMMA-SECRETASE; DOUBLE-BLIND; FOLLOW-UP; IN-VIVO;
D O I
10.1038/nm.2221
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Biomarkers may be of great value in Alzheimer's disease drug development to select the most optimal drug candidates for large and expensive phase 3 clinical trials. Biomarkers will also be important to provide evidence that a drug affects the underlying pathophysiology of the disease, which, together with a beneficial effect on the clinical course, will be essential for labeling the drug as having a disease-modifying effect.
引用
收藏
页码:1218 / 1222
页数:5
相关论文
共 45 条
[1]   A γ-Secretase Inhibitor Decreases Amyloid-β Production in the Central Nervous System [J].
Bateman, Randall J. ;
Siemers, Eric R. ;
Mawuenyega, Kwasi G. ;
Wen, Guolin ;
Browning, Karen R. ;
Sigurdson, Wendy C. ;
Yarasheski, Kevin E. ;
Friedrich, Stuart W. ;
DeMattos, Ronald B. ;
May, Patrick C. ;
Paul, Steven M. ;
Holtzman, David M. .
ANNALS OF NEUROLOGY, 2009, 66 (01) :48-54
[2]   Longitudinal stability of CSF biomarkers in Alzheimer's disease [J].
Blennow, Kaj ;
Zetterberg, Henrik ;
Minthon, Lennart ;
Lannfelt, Lars ;
Strid, Stig ;
Annas, Peter ;
Basun, Hans ;
Andreasen, Niels .
NEUROSCIENCE LETTERS, 2007, 419 (01) :18-22
[3]   Alzheimer's disease [J].
Scheltens, Philip ;
De Strooper, Bart ;
Kivipelto, Miia ;
Holstege, Henne ;
Chetelat, Gael ;
Teunissen, Charlotte E. ;
Cummings, Jeffrey ;
van der Flier, Wiesje M. .
LANCET, 2021, 397 (10284) :1577-1590
[4]   Cerebrospinal fluid and plasma biomarkers in Alzheimer disease [J].
Blennow, Kaj ;
Hampel, Harald ;
Weiner, Michael ;
Zetterberg, Henrik .
NATURE REVIEWS NEUROLOGY, 2010, 6 (03) :131-144
[5]   Donepezil effects on cerebral blood flow in older adults with mild cognitive deficits [J].
Chen, Xiying ;
Magnotta, Vincent A. ;
Duff, Kevin ;
Ponto, Laura L. Boles ;
Schultz, Susan K. .
JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2006, 18 (02) :178-185
[6]   Acute γ-Secretase Inhibition of Nonhuman Primate CNS Shifts Amyloid Precursor Protein (APP) Metabolism from Amyloid-β Production to Alternative APP Fragments without Amyloid-β Rebound [J].
Cook, Jacquelynn J. ;
Wildsmith, Kristin R. ;
Gilberto, David B. ;
Holahan, Marie A. ;
Kinney, Gene G. ;
Mathers, Parker D. ;
Michener, Maria S. ;
Price, Eric A. ;
Shearman, Mark S. ;
Simon, Adam J. ;
Wang, Jennifer X. ;
Wu, Guoxin ;
Yarasheski, Kevin E. ;
Bateman, Randall J. .
JOURNAL OF NEUROSCIENCE, 2010, 30 (19) :6743-6750
[7]  
Davidsson P, 1998, Int Psychogeriatr, V10, P11, DOI 10.1017/S1041610298005110
[8]  
Davidsson P, 1999, ELECTROPHORESIS, V20, P431
[9]   Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment [J].
DeCarli, C .
LANCET NEUROLOGY, 2003, 2 (01) :15-21
[10]   NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo [J].
Eriksen, JL ;
Sagi, SA ;
Smith, TE ;
Weggen, S ;
Das, P ;
McLendon, DC ;
Ozols, VV ;
Jessing, KW ;
Zavitz, KH ;
Koo, EH ;
Golde, TE .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (03) :440-449